EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An in situ bioadhesive foam as a large intestinal delivery platform for antibody fragment to treat inflammatory bowel disease

Wunan Zhang, Fiona McCartney, Yining Xu, Cécilia Bohns Michalowski, Inês Domingues, Espoir K Kambale, Tom G Moreels, Léo Guilbaud, Cheng Chen, Valentina Marotti, David J Brayden, Ana Beloqui

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.08.023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Wunan Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund, FRS-FNRS, Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologics have been widely used as injectables in the treatment of inflammatory bowel disease (IBD). Different local treatment attempts have been developed in recent years. However, maintaining systemic levels of biologics is still crucial for achieving colitis remission. An equilibrium between systemic and local concentrations of biologics is therefore essential for treatment of colitis. Current formulations struggle to create optimal balance between drug concentrations in plasma and the colonic wall. Addressing this challenge, we developed a rectally delivered in situ foam that generates CO2via a reaction between potassium bicarbonate (PB) and citric acid (CA) without the aid of an external device. An anti-TNF-α antibody fragment (Fab) was loaded into the foam formulation, which promoted prolonged colon retention and improved Fab distribution up to proximal colon following rectal administration to mice. In addition, we observed increased plasma Fab concentrations in mice receiving the rectal Fab foam compared to a Fab solution. In a non-everted rat gut ex vivo model, a single exposure to the CO2-containing foam improved macromolecule transepithelial flux across colonic tissue by over ten-fold. Foam efficacy for Fab was investigated in a range of colitis mouse models, from acute to chronic. This non-invasive formulation platform demonstrates potential to overcome existing limitations in delivering biologics to inflamed colonic tissue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesAnimalsMaleMice, Inbred C57BLImmunoglobulin Fab FragmentsColonTumor Necrosis Factor-alphaDrug Delivery SystemsAdministration, RectalColitisCitric AcidBicarbonatesFemaleMiceRats, Sprague-DawleyRats

Stichwörter der Autor:innen

BiologicsColonic drug deliveryFoamGas intestinal permeation enhancerInflammatory bowel disease

Substanzen

Immunoglobulin Fab FragmentsTumor Necrosis Factor-alphaCitric AcidBicarbonates

Autor:innen und Institutionen

  • UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium.
  • University College Dublin School of Veterinary Medicine and Conway Institute, Belfield, Dublin D4, Ireland.
  • UCLouvain, Université Catholique de Louvain, Institute of Experimental and Clinical Research, Laboratory of Hepato-Gastroenterology, 1200 Brussels, Belgium.
  • UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium; WEL Research Institute, Avenue Pasteur, 6, 1300 Wavre, Belgium. Electronic a…

Förderung

  • European Regional Development Fund
  • FRS-FNRS
  • Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture

Zitieren

APA

Zhang, W., McCartney, F., Xu, Y., Michalowski, C. B., Domingues, I., Kambale, E. K., Moreels, T. G., Guilbaud, L., Chen, C., Marotti, V., Brayden, D. J., & Beloqui, A. (2024). An in situ bioadhesive foam as a large intestinal delivery platform for antibody fragment to treat inflammatory bowel disease. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.08.023

Vancouver

Zhang W, McCartney F, Xu Y, Michalowski CB, Domingues I, Kambale EK, et al. An in situ bioadhesive foam as a large intestinal delivery platform for antibody fragment to treat inflammatory bowel disease. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.08.023

BibTeX
@article{Zhang2024,
  author = {Zhang, Wunan and McCartney, Fiona and Xu, Yining and Michalowski, Cécilia Bohns and Domingues, Inês and Kambale, Espoir K and Moreels, Tom G and Guilbaud, Léo and Chen, Cheng and Marotti, Valentina and Brayden, David J and Beloqui, Ana},
  title = {An in situ bioadhesive foam as a large intestinal delivery platform for antibody fragment to treat inflammatory bowel disease},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.08.023}
}
Kostenlos starten →